Quick Answer
Unicycive Therapeutics, Inc. reported Diluted EPS of $1.67 per share (loss) for fiscal year 2025.
Unicycive Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.67 | +70.4% |
| 2024 | -$5.65 | -341.4% |
| 2023 | -$1.28 | -6.7% |
| 2022 | -$1.20 | -39.5% |
| 2021 | -$0.86 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.33 | +28.3% | +36.5% |
| June 30, 2025 | -$0.52 | +65.3% | -940.0% |
| March 31, 2025 | -$0.05 | +91.8% | +89.1% |
| September 30, 2024 | -$0.46 | -253.8% | +69.3% |
| June 30, 2024 | -$1.50 | -417.2% | -145.9% |
| March 31, 2024 | -$0.61 | +37.1% | -369.2% |
| September 30, 2023 | -$0.13 | +64.9% | +55.2% |
| June 30, 2023 | -$0.29 | -20.8% | +70.1% |
- Unicycive Therapeutics, Inc. showed an increase of +70.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Unicycive Therapeutics, Inc.’s diluted eps has declined by 94.2% (from $0.86 per share (loss) to $1.67 per share (loss)).
- The most recent figure is from Unicycive Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: